Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Minoxidil 5% w/v cutaneous spray, solution

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Minoxidil may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Minoxidil
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Minoxidil is a medicine for topical application to the scalp that stimulates hair growth in men aged 1865 with male-pattern hair loss (men with a family history of hair loss). The start of hereditary hair loss in men is characterised by the thinning of the frontal hairline at the temples with the formation of a receding hairline. Later on, there is also increasing hair loss on the crown of the head. The following illustrations show the stages of male-pattern hair loss.

You must talk to a doctor if you do not feel better or if you feel worse after 4 months. 2.

What you need to know before you take it

e Minoxidil

Do not use Minoxidil

  • if you are allergic to minoxidil or any of the other ingredients of this medicine (listed in section 6)
  • if you are a female
  • if you are under the age of 18 and over the age of 65
  • if you are using any other medicines on the scalp
  • if you have any kind of dressing or bandage on your scalp
  • if you suffer from sudden or uneven hair loss 1 V04
  • if you have any condition that affects your scalp, including psoriasis (an itchy inflammatory skin condition), sunburn, shaved scalp or if your scalp skin is damaged by scars or burns, since no hair roots are present
  • if you have total baldness or complete loss of all body hair
  • if you have any signs of cardiovascular disease or heart rhythm problems
  • if you have suffer from high blood pressure
  • if you have a red, inflamed or painful scalp
  • if you do not know why you are losing your hair
  • if you are not sure if your hair loss is hereditary. Warnings and precautions You should not use Minoxidil  if you have any signs of cardiovascular disease or heart rhythm problems  if you suffer from high blood pressure  if you are using medicines to treat high blood pressure (antihypertensive agents). Talk to you doctor or pharmacist before using Minoxidil  if you have abnormal hormonal levels, a disease affecting the whole body or a lack of sufficient nutrition in the body. In these cases, your treatment may need to be adjusted  if you are at all unsure whether your scalp is normal and healthy. You should stop Minoxidil and consult a doctor  if you are found to have low blood pressure or if one or more of the following symptoms appear: chest pain, faster heartbeat, weakness or dizziness, sudden and unexplained weight gain, swollen hands or feet, persistent redness or irritation of the scalp or if other not expected new symptoms appear (see section "If you use more Minoxidil than you should"). Apply Minoxidil only to a normal healthy scalp. You should not use Minoxidil if the cause of hair loss is not known or if the scalp is red, inflamed or painful. There is no clinical experience to date regarding its effectiveness for hair loss in the temporal region (receding hairline). If effects on inner organs (systemic effects) or severe skin reactions occur, the product must be discontinued. Minoxidil is intended only for external use only on the scalp. Do not apply Minoxidil to other parts of the body. Unwanted hair growth may be caused by the transfer of the product to areas other than the scalp. Wash your hands thoroughly before and after applying the solution and rinse other areas that have come into contact with the solution. Isolated cases of slight changes in hair colour have been reported by patients with very fair hair when using hair care products at the same time, or after swimming in heavily chlorinated water. Accidental ingestion can cause serious side effects on the cardiovascular system. Therefore, you must keep this medicine out of the reach of children. Avoid breathing in the spray mist. Minoxidil 5% w/v cutaneous spray, solution is flammable. Do not use near an open flame, lit cigarettes or some devices (e.g. hairdryers). Children and adolescents 2 V04

Do not give this medicine to children and adolescents below 18 years as safety and effectiveness in this age group have not been established. Cases of excessive hair growth on the body of infants have been reported following skin contact with minoxidil application sites of patients (caregivers) using topical minoxidil. Hair growth returned to normal within months when infants were no longer exposed to minoxidil. Care should be taken to ensure that children do not come into contact with areas of your body where you have applied minoxidil topically. Consult a doctor if you notice excessive hair growth on the body of your child during the period you are using topical minoxidil products. Other medicines and Minoxidil Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any other medicines. To date, no information is available on interactions between Minoxidil and other agents. Although not clinically proven, there is a theoretical possibility that absorption of the active substance in Minoxidil (minoxidil) into the body may worsen orthostatic hypotension (a drop in blood pressure felt when standing up from a lying position) in patients who are also taking peripheral vasodilators (certain high blood pressure medicines which widen the blood vessels). Guanethidine is an example of an antihypertensive drug that may interact with minoxidil. Minoxidil should not be used together with other dermatological products (preparations for external use containing active substances such as corticosteroids, retinoids, petrolatum or dithranol) or with agents that increase absorption of the active substance through the skin (skin absorption). Pregnancy and breast-feeding Minoxidil is for use in male patients only. There is only limited experience with the application of Minoxidil during pregnancy. Minoxidil incorporated into the body can pass into breast milk. Thus, Minoxidil must not be used by pregnant women and breast-feeding mothers. Driving and using machines This medicinal product may cause dizziness or low blood pressure. If affected, patients should not drive or operate machinery. Minoxidil contains propylene glycol and alcohol (ethanol 96 per cent) This medicine contains 350 mg propylene glycol in each ml of solution. This medicine contains 510 mg of alcohol (ethanol) in each ml of solution. It may cause burning sensation on damaged skin. Ethanol can cause eye stinging and irritation. In case of accidental contact with sensitive areas (eyes, skin abrasions, mucous membranes), you must rinse these with plenty of water. If you apply Minoxidil repeatedly on your hair rather than your scalp, this might lead to increased hair dryness and/or stiffness due to the ethanol and propylene glycol content in Minoxidil. 3.

How to take it

Minoxidil

Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Minoxidil is intended for external use on the dry scalp. Please use Minoxidil only on healthy, undamaged scalp and follow the instructions for use below exactly at all times. Do not apply Minoxidil to body areas other than the scalp. 3 V04

The recommended dose is: Apply 1 ml Minoxidil twice daily (morning and evening) to the affected areas in the crown region of the scalp. The daily amount applied of 2 x 1 ml solution should not be exceeded, regardless of the size of the affected skin area. Leave at least 12 hours between each use. Use in children and adolescents Minoxidil must not be used in children and adolescents below 18 years, as no effectiveness and safety results from controlled studies are available in these age groups. Method of administration Minoxidil is intended only for external use and only on the scalp. Each pack of Minoxidil solution contains 2 different application devices:

  • pre-assembled spray-pump for large-area application
  • separate applicator with extended tip for smaller areas Both applicators can be swapped by detaching the one applicator and replacing it with the other. Prior to applying minoxidil, it must be ensured that the scalp is dry. Minoxidil should not be applied to other parts of the body. Instructions for use/application According to the affected area and the application device provided. A. Spray pump

1. Remove the outer cap of the bottle. 2. Apply 1 ml of solution, by pressing the spray pump 6 times (Fig. 1). After each pumping action, spread the liquid over the affected area with your fingertips. At the same time, avoid breathing in the spray mist.

Fig. 1 For a more localised application (small areas of the scalp or under the hair), use the applicator provided with the pack. B. Applicator

1. Remove the outer cap of the bottle. 2. Remove the top part of the spray head (piece with the orifice), by pulling it up (Fig. 2), and insert the applicator (Fig. 3 and 4). 3. Apply 1 ml of solution, by pressing the applicator 6 times (Fig. 5).

Fig. 2

Fig 3

After each pumping action, spread the liquid over the affected area with your fingertips. At 4

V04

the same time, avoid breathing in the spray mist.

Fig. 4

Fig. 5

Spray pump and applicator cleaning Remove the top part of the spray head or applicator and rinse with isopropyl alcohol (70 per cent) after each use to clean the product residues and to avoid clogging. After cleaning, place back the removed parts (either the spray pump and outer cap or the spray-tip applicator). What else must you bear in mind during use? Hands should be washed carefully after applying Minoxidil, in order to avoid accidental contact with moist lining of the mouth, nose and eyes. After applying Minoxidil, you can style your hair as normal. However, you should not moisten the scalp for about 4 hours. This will prevent Minoxidil from being washed off. Information about increased hair loss In the treatment of hair follicles with the active substance minoxidil, the resting phase (telogen phase) of the hair cycle is shortened and the growth phase (anagen phase) is reached more quickly. This stimulates new hair growth, which pushes the "old", no longer active hairs out of the scalp. This gives the initial impression of increased hair loss. In some patients, this reaction has been observed two to six weeks after the start of treatment with the active substance minoxidil. However, there is no need to be alarmed, as this reaction is accompanied by increased hair regrowth. The effect wears off within a few weeks and may be interpreted as a first sign of the minoxidil effect. If hair loss persists for more than 2 weeks, you should stop using Minoxidil and consult your doctor. Duration of use The onset and extent of hair growth are different in individual patients. In general, twice-daily treatment for 2 to 4 months is required before an effect is seen. In order to maintain the effect, it is recommended to continue the twice-daily application without interruption. You will not achieve any better result by applying Minoxidil in larger amounts or more frequently. Regarding a possible therapeutic effect, there is sufficient clinical experience for a treatment period of up to one year. If no effect is seen after 12 months, treatment should be discontinued. Please talk to your doctor or pharmacist if you have the impression that the effect of Minoxidil is too strong or too weak. If you use more Minoxidil than you should Application of Minoxidil at higher than the recommended dosage and to relatively large body surfaces or areas other than the scalp may possibly lead to increased absorption of minoxidil into the body. To date, there have been no known cases where the external use of minoxidil solution has resulted in symptoms of poisoning. If swallowed accidentally, the concentration of the active compound minoxidil in Minoxidil may lead to effects on the inner organs corresponding to the effects which result when the active substance is 5 V04

swallowed, e.g. in a tablet. This may cause the following side effects: faster heartbeat, drop in blood pressure, fluid accumulation and subsequent sudden weight gain, dizziness. In case of accidental ingestion or signs of overdose, please tell a doctor immediately, so that he/she can decide what to do next. Please keep the medicine pack ready to hand, so that the doctor can be informed about what active substance has been taken. If you forget to use Minoxidil Do not apply a double dose to make up for a forgotten dose; continue your treatment at the recommended dose. Making up for the missed dose will bring no benefit and might lead to undesirable effects. If you stop using Minoxidil It is necessary to continue treatment to improve and maintain hair growth. Otherwise, hair loss will reoccur. Within 3 to 4 months after interruption of the treatment with Minoxidil the untreated area will look like it did before the treatment started. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact a doctor right away if you notice any of the following symptoms – you may need urgent medical treatment:           

Chest pain Swelling of the face, lips or throat which makes it difficult to swallow or breathe. This could be a sign of a severe allergic reaction (frequency not known, cannot be estimated from the available data). Generalised redness of the skin (frequency not known, cannot be estimated from the available data) Generalised itching (frequency not known, cannot be estimated from the available data) Tightness in the throat (frequency not known, cannot be estimated from the available data) Low blood pressure Faster heartbeat Weakness or dizziness Sudden and unexplained weight gain Swollen hands or feet Persistent redness or irritation of the scalp or if other not expected new symptoms appear

Very common (may affect more than 1 in 10 people):  Headache Common (may affect up to 1 in 10 people):  Itching  Increased hair growth beyond the scalp (including facial hair growth in women), inflammatory skin reaction (including acneiform rash, skin rash)  Shortness of breath, difficulty in breathing  Swollen arms and legs  Weight gain  High blood pressure  Irritation of the scalp such as stinging, burning, dryness, itching, scaling, infected or inflamed hair follicles

6 V04

Uncommon (may affect up to 1 in 100 people):  Dizziness, nausea Rare (may affect up to 1 in 1,000 people)  Change in hair texture may occur. If this happens, you should stop using Minoxidil. Not known (frequency cannot be estimated from the available data):  Contact dermatitis (allergy-related inflammation of the skin)  Depressed mood  Eye irritation  Faster heartbeat, palpitations, low blood pressure  Vomiting  Symptoms at the administration site which may also affect the ears and face, such as itching, skin irritation, pain, redness, swelling, dry skin and inflammatory rash up to possible skin peeling, skin inflammation (dermatitis), blistering, bleeding and ulceration  Temporary hair loss, changes in hair colour Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5.

How to store it

Minoxidil

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and bottle after "EXP". The expiry date refers to the last day of that month. Do not refrigerate or freeze. Keep the bottle tightly closed. Shelf life after first opening: 1 year. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Minoxidil contains The active substance is minoxidil. Each millilitre of solution contains 50 mg of minoxidil. The other ingredients are: propylene glycol and ethanol (96 per cent). What Minoxidil looks like and contents of the pack Clear, colourless to yellowish homogeneous solution, free from particles. 7 V04

The solution is provided in red transparent bottle, closed with a red spray-pump with an applicator. Pack sizes: 1 x 60 ml and 3 x 60 ml solution Not all pack sizes may be marketed. Marketing Authorisation Holder axunio Pharma GmbH Van-der-Smissen-Straße 1 22767 Hamburg Germany Distributor: Manual Pharmacy Unit 1,Verda Park, Hithercroft Road, Wallingford, OX10 9SJ United Kingdom Manufacturer Medinfar Manufacturing, S.A. Parque Industrial Armando Martins Tavares Rua Outeiro da Armada, 5 Condeixa-a-Nova 3150-194 Sebal Portugal This leaflet was last revised in December 2024.

8 V04

Frequently asked questions about Minoxidil 5% w/v cutaneous spray, solution

How do I take Minoxidil 5% w/v cutaneous spray, solution?

Minoxidil 5% w/v cutaneous spray, solution comes as spray. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Minoxidil 5% w/v cutaneous spray, solution?

The active substance in Minoxidil 5% w/v cutaneous spray, solution is minoxidil.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Minoxidil 5% w/v cutaneous spray, solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Minoxidil 5% w/v cutaneous spray, solution without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Minoxidil (8 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Minoxidil 5% w/v cutaneous spray, solution is indicated for the treatment of alopecia androgenetica in men.

Onset and degree of hair regrowth may be variable among users. Although trends in the data suggest that those users who are younger, who have been balding for a shorter period of time or who have a smaller area of baldness on the vertex are more likely to respond to Minoxidil 5% w/v cutaneous spray, solution individual responses cannot be predicted.

4.2. Posology and method of administration

Men aged 18-65:

Posology

1 ml Minoxidil should be applied twice daily (morning and evening) to the affected areas of the scalp.

The daily amount applied of 2 x 1 ml solution should not be exceeded, regardless of the size of the affected scalp area.

Too low dosage

If too little minoxidil has been applied or a dose has been missed, the patient must not make up for the missing amount. In this case, treatment should be continued at the recommended dose.

Special populations

There are no specific recommendations for use in patients with renal or hepatic impairment.

Paediatric and Elderly populations

Not recommended. The safety and effectiveness of Minoxidil 5% w/v cutaneous spray, solution in children and adolescents below the age of 18 years or adults over 65 years has not been established.

Method of administration

Minoxidil should only be used on the scalp.

Each pack of Minoxidil solution contains 2 different pump spray applicators:

- pre-assembled applicator for large-area application

- separate applicator with extended tip for smaller areas

Both applicators can be swapped by detaching the one applicator and replacing it with the other.

Prior to applying minoxidil, it must be ensured that the scalp is dry.

Minoxidil should not be applied to other parts of the body.

Hands should be washed carefully after applying minoxidil, in order to avoid accidental contact with mucous membranes and eyes.

After applying minoxidil, the hair can be styled as normal. However, the scalp should not be moistened for about 4 hours. This will prevent minoxidil from being washed off.

Instructions for use/application

According to the affected area and the application device provided.

A. Spray pump

1. The outer cap of the bottle should be removed.

2. 1 ml of solution should be applied, by pressing the spray pump 6 times (Fig. 1).

After each pumping action, the patient should spread the liquid over the affected area with their fingertips. At the same time, inhalation of the spray mist should be avoided.

For a more localised application (small areas of the scalp or under the hair), the applicator provided with the pack should be used.

B. Applicator

1. The outer cap of the bottle should be removed.

2. The top part of the spray head (piece with the orifice) should be removed by pulling it up (Fig. 2), and the applicator should be inserted (Fig. 3 and 4).

3. 1 ml of solution should be applied by pressing the applicator 6 times (Fig. 5).

After each pumping action, the patient should spread the liquid over the affected area with their fingertips. At the same time, inhalation of the spray mist should be avoided.

Duration of use

The onset and extent of hair growth are different in individual patients.

In general, twice-daily treatment for 2 to 4 months is required before an effect is seen. In order to maintain the effect, it is recommended to continue the twice-daily application without interruption. Anecdotal reports indicate that regrown hair may disappear three to four months after stopping Minoxidil 5% w/v cutaneous spray, solution application and the balding process will continue. Applying minoxidil in larger amounts or more frequently does not achieve better results. Regarding a possible therapeutic effect, there is sufficient clinical experience for a treatment period of up to one year.

If no effect is seen after 12 months, treatment should be discontinued.

4.3. Contraindications

- hypersensitivity to the active substance or to any of the excipients listed in section 6.1,

- in users with treated or untreated hypertension

- in women, due to occasional signs of cosmetically distressing, reversible, facial hair growth during treatment,

- use of occlusive dressings or other topical medical preparations on the scalp,

- sudden or uneven hair loss

- in patients with any scalp abnormality (including psoriasis, sunburn, shaved scalp or if the scalp is damaged by burns or scarring).

4.4. Special warnings and precautions for use

Prior to treatment with minoxidil, the patient should be thoroughly examined, and her/his medical history taken.

Endocrinological causes, underlying systemic diseases or malnutrition must be excluded. In these cases, if necessary, a specific treatment should be initiated.

The patient should have a normal, healthy scalp. Minoxidil should not be used if the cause of hair loss is not known, if the scalp is infected or if the scalp is red, inflamed or painful.

Topical minoxidil is only indicated for the treatment of alopecia androgenetica and should not be used in other types of hair loss for example when there is no family history of hair loss, hair loss is sudden and/or patchy, hair loss is due to childbirth, or the reason for hair loss is unknown. Minoxidil is intended only for external use on the scalp and should not be applied to other parts of the body.

There is no clinical experience to date with regard to efficacy for hair loss in the temporal region (receding hairline).

The patient should discontinue the medicinal product and consult a doctor if a reduction in blood pressure is detected, or if one or more of the following manifestations occur: chest pain, accelerated heartbeat, asthenia or dizziness, sudden unexplained weight gain, swollen hands or feet, persistent redness or irritation of the scalp or if other not expected new symptoms appear (see section 4.8).

In some patients, a transient increase in the amount of hair shedding has been observed two to six weeks after the start of treatment. This effect is due to the fact that the resting phase (telogen phase) of the hair cycle is shortened in hair follicles treated with minoxidil and the growth phase (anagen phase) is reached more quickly. This stimulates new hair growth, which pushes the “old”, no longer active hairs out of the scalp. This gives the initial impression of increased hair loss. However, it is accompanied by increased hair regrowth. This effect regresses within a few weeks and can be interpreted as a first sign of the minoxidil effect. Using more than the recommended dose or more often will not improve results. If shedding persists (>2 weeks), users should stop Minoxidil 5% w/v cutaneous spray, solution application and consult their doctor.

Unwanted hair growth may be caused by the transfer of the medicinal product to areas other than the scalp.

Treatment with minoxidil should not take place in patients with signs of cardiovascular disease or cardiac arrhythmias or in hypertensive patients, including patients on treatment with antihypertensives.

Isolated cases of slight changes in hair colour have been reported by patients with very fair hair upon concomitant use of hair care products or after swimming in heavily chlorinated water. Users should be aware that, whilst extensive use of Minoxidil 5% w/v cutaneous spray, solution has not revealed evidence that sufficient minoxidil is absorbed to have systemic effects, greater absorption because of misuse, individual variability, unusual sensitivity or decreased integrity of the epidermal barrier caused by inflammation or disease processes in the skin (e.g. excoriations of the scalp, or scalp psoriasis) could lead, at least theoretically, to systemic effects.

Hypertrichosis in children following inadvertent topical exposure to minoxidil:

Cases of hypertrichosis have been reported in infants following skin contact with minoxidil application sites of patients (caregivers) using topical minoxidil. Hypertrichosis was reversible, within months, when infants were no longer exposed to minoxidil. Contact between children and minoxidil application sites should therefore be avoided.

Inadvertent ingestion can cause severe cardiovascular adverse reactions. This product must therefore be kept out of the reach of children.

When treatment with minoxidil is stopped, shedding of the hairs will occur again.

Due to the ethanol and propylene glycol content in minoxidil, repeated spraying of minoxidil on the hair rather than the scalp might result in increased hair dryness and/or stiffness.

Inhalation of the spray mist should be avoided.

Minoxidil 5% w/v cutaneous spray, solution is flammable. It should not be used near an open flame, lit cigarettes or some devices (e.g. hairdryers).

Minoxidil 5% w/v cutaneous spray, solution contains ethanol 96%. It may cause burning sensation on damaged skin.

It can also cause eye stinging and irritation. In case of accidental contact with sensitive areas (eyes, skin abrasions, mucous membranes), these must be rinsed with plenty of water.

This medicine contains 350 mg of propylene glycol in each 1 ml. Propylene glycol may cause skin irritation. Because this medicine contains propylene glycol, do not use it on open wounds or large areas of broken or damaged skin (such as burns) without checking with your doctor or pharmacist.

4.5. Interaction with other medicinal products and other forms of interaction

To date, no information is available on interactions between minoxidil and other medicinal products. Although not clinically proven, there is a theoretical possibility that absorbed minoxidil may potentiate orthostatic hypotension in patients concomitantly taking peripheral vasodilators.

Minoxidil should not be used on the scalp together with other dermatological products (or with agents that enhance skin absorption).

Pharmacokinetic drug interaction studies in humans showed that the percutaneous absorption of minoxidil is enhanced by tretinoin, corticosteroids, petrolatum and dithranol as a result of increased permeability of the stratum corneum. Betamethasone dipropionate increases the local tissue concentration of minoxidil and reduces the systemic absorption of minoxidil.

Guanethidine has been reported to interact with oral formulations of minoxidil resulting in rapid and pronounced lowering of blood pressure.

There is a theoretical possibility that topical minoxidil may also interact with guanethidine.

4.6. Fertility, pregnancy and lactation

Minoxidil is indicated for use in male patients only and must not be used by pregnant women and breastfeeding mothers.

Pregnancy

There are no adequate and well controlled studies in pregnant women. Studies in animals have shown a risk to the foetus at exposure levels that are very high compared to those intended for human exposure. There is potentially a risk of foetal harm in humans (see section 5.3).

Breast-feeding

Systemically absorbed minoxidil is excreted in human milk. The effect of minoxidil on new-borns/infants is unknown.

Fertility

Minoxidil caused a dose-dependent decrease in the conception rate in rats. Due to the low systemic exposure following topical administration, the clinical relevance is probably limited.

4.7. Effects on ability to drive and use machines

This medicinal product may cause dizziness or hypotension (see section 4.8). If affected, patients should not drive or operate machinery.

4.8. Undesirable effects

The following frequencies are used for the evaluation of adverse reactions:

Very common

(≥1/10)

Common

(≥1/100 to <1/10)

Uncommon

(≥1/1,000 to <1/100)

Rare

(≥1/10,000 to <1/1,000)

Very rare

(<1/10,000)

Not known

(cannot be estimated from the available data)

The safety of topical minoxidil from clinical trial data is based on data from 7 placebo-controlled randomised clinical trials in adults evaluating either 20 mg/ml or 50 mg/ml minoxidil solution, and two placebo-controlled randomised clinical trials in adults evaluating a 50 mg/ml foam formulation.

Adverse drug reactions (ADRs) identified during clinical trials and post-marketing experience with minoxidil are included in the table below by System Organ Class (SOC).

System Organ Class (SOC)

Frequency

Adverse Drug Reaction (ADR)

Immune System Disorders

Not known

Allergic reactions including angioedema (with symptoms such as oedema of the lips, mouth, tongue and throat, swelling of the lips, tongue and oropharynx)

Common

Hypersensitivity (including facial oedema, generalised skin rash, general pruritus, facial swelling and throat tightness)

Psychiatric Disorders

Not known

Depressed mood

Nervous System Disorders

Very common

Headache

Uncommon

Dizziness

Eye disorders

Not known

Eye irritation

Cardiac disorders

Not known

Tachycardia, palpitations

Common

Chest pain

Vascular disorders

Common

Hypertension

Not known

Hypotension

Respiratory, thoracic and mediastinal disorders

Common

Dyspnoea

Gastrointestinal Disorders

Uncommon

Nausea

Not known

Vomiting

Skin and subcutaneous tissue disorders

Common

Pruritus, hypertrichosis (including facial hair growth in women), dermatitis, dermatitis acneiform, skin rash, local side effects on the scalp: stinging, burning, itching, dryness, scaling and folliculitis

Not known

Symptoms at the administration site which may also affect the ears and face, such as pruritus, skin irritation, pain, redness, oedema, dry skin and inflammatory rash up to exfoliation, dermatitis, blisterin, bleeding and ulceration

Temporary hair loss (see section 4.4)

Changes in hair colour

Rare

Changes in hair texture

Not known

Application site reactions (These sometimes involve nearby structures like the ears and face and typically consist of pruritus, irritation, pain, rash, oedema, dry skin, erythema and rash erythematous but can sometimes be more severe and include exfoliation, dermatitis, blistering, bleeding and ulceration)

General disorders and administration site conditions

Common

Peripheral oedema

Not known

Chest pain

Investigations

Common

Weight increased

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Symptoms of intoxication

Application of minoxidil at higher than the recommended dosage and to relatively large body surfaces or areas other than the scalp may possibly lead to increased systemic absorption of minoxidil. To date, there have been no known cases where the topical use of minoxidil solution has resulted in intoxication.

After inadvertent swallowing, the concentration of the active compound minoxidil in this medicinal product may lead to systemic effects corresponding to the pharmacological action of the active substance (2 ml minoxidil 50 mg/ml contains 100 mg minoxidil, which is equivalent to the maximum recommended daily dose for the treatment of hypertension).

Due to the systemic effects of minoxidil, the following adverse reactions may occur:

Cardiac disorders: accelerated heartbeat, hypotension

General disorders: fluid accumulation and subsequent sudden weight gain

Nervous system disorders: dizziness

Treatment of intoxication

Clinically significant tachycardia can be controlled with β-blockers and oedema with diuretics.

An excessive decrease in blood pressure can be treated by intravenous infusion of physiological saline solution. Sympathomimetics such as adrenaline and noradrenaline are to be avoided due to their excessive cardiotonic effect.

Treatment of minoxidil overdosage should be symptomatic and supportive.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • ALOPEXY 20mg/ml over the counterMINOXIDILUM · skin / topical
  • REGAINE 50 mg/g over the counterMINOXIDILUM · skin / topical
  • MINORGA 20 mg/ml over the counterMINOXIDILUM · skin / topical
  • MINORGA 50 mg/ml over the counterMINOXIDILUM · skin / topical
  • REGAINE FEMINA 50 mg/g over the counterMINOXIDILUM · skin / topical
  • MINOXIDIL MEDINFAR 20 mg/ml over the counterMINOXIDILUM · skin / topical

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.

  • Loxon 2%Minoxidilum
  • PiloxidilMinoxidilum
  • Loxon MaxMinoxidilum
  • AlopexyMinoxidilum · taken by mouth
  • MinorgaMinoxidilum · taken by mouth
  • Alocutan ForteMinoxidilum · inhaler / nebuliser

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Minoxidil 5% w/v cutaneous spray, solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →